Novartis again shared a reassuring outlook, with promising sales growth and margin expansion targets. The only difference now is that the firm has clarity on Sandoz and all its efforts can be channelled towards unlocking the potential of its legacy stronghold pharma franchise. Overall, with a good mix of multi-blockbuster assets, a broad-based pipeline – also including some interesting advanced treatment frontier assets, and being open to bolt-ons, Novartis remains on the right track to navigate ....
